Compare RECT & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RECT | TENX |
|---|---|---|
| Founded | 1997 | 1967 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 56.2M |
| IPO Year | 2024 | N/A |
| Metric | RECT | TENX |
|---|---|---|
| Price | $1.82 | $10.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 11.2K | ★ 157.3K |
| Earning Date | 07-31-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $32,594,177.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.61 | ★ N/A |
| Revenue Growth | ★ 5.91 | N/A |
| 52 Week Low | $1.79 | $4.63 |
| 52 Week High | $7.68 | $10.65 |
| Indicator | RECT | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 27.15 | 75.73 |
| Support Level | $1.79 | $9.40 |
| Resistance Level | $2.12 | $10.55 |
| Average True Range (ATR) | 0.11 | 0.57 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 9.09 | 88.62 |
Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks. Additionally the company has added auxiliary products such as industrial hardware tools and electrical hardware required for construction sites.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.